What's in MAYNE PHARMA's pipeline?

MAYNE PHARMA has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with MAYNE PHARMA's portfolio?

Top competitors by shared drug class: , Pfizer, Duramed Res, Merck & Co., Oregon Health and Science University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mayne-pharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

MAYNE PHARMA — Portfolio Competitive Intelligence Brief

MAYNE PHARMA pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Nextstellis	ESTETROL	marketed	Estrogen	Estrogen receptor	Other	2021-01-01
Annovera	SEGESTERONE	marketed	Estrogen [EPC]		Other	2018-01-01
Benzamycin	BENZOYL PEROXIDE	marketed	benzoyl peroxide		Immunology	1984-01-01

Therapeutic area mix

Other · 2
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 2 shared drug classes
Pfizer · 2 shared drug classes
Duramed Res · 1 shared drug class
Merck & Co. · 1 shared drug class
Oregon Health and Science University · 1 shared drug class
Wyeth Pharms Pfizer · 1 shared drug class
Pfizer Inc. · 1 shared drug class
Ph Health · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MAYNE PHARMA:

Cite this brief

Drug Landscape (2026). MAYNE PHARMA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mayne-pharma. Accessed 2026-05-15.